PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives

Fakiri, Mohamed El; Geis, Nicolas; Ayada, Nawal; Eder, Matthias

doi:10.3390/cancers13163967

Cited by 27 publications

(17 citation statements)

References 191 publications

(320 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, mAbs have a prolonged circulation time due to their large size (218). In this regard, the third generation mAbs (minibodies/diabodies) were developed (219,220). [ 89 Zr]Zr-IAB2M, a minibody, showed a favorable biodistribution (221) and promising diagnostic performance compared to magnetic resonance imaging (MRI) and [ 68 Ga]Ga-PSMA PET/CT (222).…”

Section: Prostate Cancermentioning

confidence: 99%

ImmunoPET: Antibody-Based PET Imaging in Solid Tumors

et al. 2022

View full text Add to dashboard Cite

Immuno-positron emission tomography (immunoPET) is a molecular imaging modality combining the high sensitivity of PET with the specific targeting ability of monoclonal antibodies. Various radioimmunotracers have been successfully developed to target a broad spectrum of molecules expressed by malignant cells or tumor microenvironments. Only a few are translated into clinical studies and barely into clinical practices. Some drawbacks include slow radioimmunotracer kinetics, high physiologic uptake in lymphoid organs, and heterogeneous activity in tumoral lesions. Measures are taken to overcome the disadvantages, and new tracers are being developed. In this review, we aim to mention the fundamental components of immunoPET imaging, explore the groundbreaking success achieved using this new technique, and review different radioimmunotracers employed in various solid tumors to elaborate on this relatively new imaging modality.

show abstract

Section: Prostate Cancermentioning

confidence: 99%

ImmunoPET: Antibody-Based PET Imaging in Solid Tumors

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Most importantly, it led to fundamental advances for the development of external beam-based radiation therapy (RT) protocols for the treatment of cancer, including (a) the use of different IR sources, (b) progress in studies on radiation physics, (c) incorporation of advanced computer technologies to the treatment planning, and (d) technologically advanced equipment that facilitates the precise delivery of radiation to the tumors with minimal damage to the normal tissues [3,4]. Although protocols for the internal delivery of radiation to tumors such as brachytherapy [5][6][7], the localized implant of radioactive seeds into, or as near as possible to, the tumor tissues, as well as the systemic treatment with tumor-specific, receptor-targeted radiopharmaceuticals [8][9][10], have become valuable and effective alternatives or complements to external-beam RT, this review will focus on the influence of the microbiota and the use of antibiotics on cancer patient outcomes after treatment with external-beam RT.…”

Section: Introductionmentioning

confidence: 99%

The Interplay among Radiation Therapy, Antibiotics and the Microbiota: Impact on Cancer Treatment Outcomes

2022

View full text Add to dashboard Cite

Radiation therapy has been used for more than a century, either alone or in combination with other therapeutic modalities, to treat most types of cancer. On average, radiation therapy is included in the treatment plans for over 50% of all cancer patients, and it is estimated to contribute to about 40% of curative protocols, a success rate that may reach 90%, or higher, for certain tumor types, particularly on patients diagnosed at early disease stages. A growing body of research provides solid support for the existence of bidirectional interaction between radiation exposure and the human microbiota. Radiation treatment causes quantitative and qualitative changes in the gut microbiota composition, often leading to an increased abundance of potentially hazardous or pathogenic microbes and a concomitant decrease in commensal bacteria. In turn, the resulting dysbiotic microbiota becomes an important contributor to worsen the adverse events caused in patients by the inflammatory process triggered by the radiation treatment and a significant determinant of the radiation therapy anti-tumor effectiveness. Antibiotics, which are frequently included as prophylactic agents in cancer treatment protocols to prevent patient infections, may affect the radiation/microbiota interaction through mechanisms involving both their antimicrobial activity, as a mediator of microbiota imbalances, and their dual capacity to act as pro- or anti-tumorigenic effectors and, consequently, as critical determinants of radiation therapy outcomes. In this scenario, it becomes important to introduce the use of probiotics and/or other agents that may stabilize the healthy microbiota before patients are exposed to radiation. Ultimately, newly developed methodologies may facilitate performing personalized microbiota screenings on patients before radiation therapy as an accurate way to identify which antibiotics may be used, if needed, and to inform the overall treatment planning. This review examines currently available data on these issues from the perspective of improving radiation therapy outcomes.

show abstract

“…For example, AuNPs have been proposed as theranostic agents, with complementary uses both in therapy and diagnostics, especially within the field of targeted radionuclide therapy [12] . Targeted radionuclide therapy has recently been shown to be effective to treat metastatic castration‐resistant prostate cancer (mCRPC) patients where conventional therapies have failed [13,14] . As AuNPs can be stably labeled with the theranostic pair copper‐64/copper‐67 [15,16] or with other radionuclides for example with the alpha‐emitter astatine‐211, [17,18] AuNPs could play an essential role in future theranostic applications.…”

Section: Introductionmentioning

confidence: 99%

Bioorthogonal Click of Colloidal Gold Nanoparticles to Antibodies In vivo

Poulie

Sporer

Hvass

et al. 2022

Chemistry A European J

View full text Add to dashboard Cite

Combining nanotechnology and bioorthogonal chemistry for theranostic strategies offers the possibility to develop next generation nanomedicines. These materials are thought to increase therapeutic outcome and improve current cancer management. Due to their size, nanomedicines target tumors passively. Thus, they can be used for drug delivery purposes. Bioorthogonal chemistry allows for a pretargeting approach. Higher target-to-background drug accumulation ratios can be achieved. Pretargeting can also be used to induce internalization processes or trigger controlled drug release. Colloidal gold nanoparticles (AuNPs) have attracted widespread interest as drug delivery vectors within the last decades. Here, we demonstrate for the first time the possibility to successfully ligate AuNPs in vivo to pretargeted monoclonal antibodies. We believe that this possibility will facilitate the development of AuNPs for clinical use and ultimately, improve state-of-the-art patient care.

show abstract

PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives

Cited by 27 publications

References 191 publications

ImmunoPET: Antibody-Based PET Imaging in Solid Tumors

ImmunoPET: Antibody-Based PET Imaging in Solid Tumors

The Interplay among Radiation Therapy, Antibiotics and the Microbiota: Impact on Cancer Treatment Outcomes

Bioorthogonal Click of Colloidal Gold Nanoparticles to Antibodies In vivo

Contact Info

Product

Resources

About